17亿港元!高瓴资本清仓金斯瑞蓬勃生物

药事纵横
02 May

声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。4月28日,金斯瑞发布公告宣布金斯瑞蓬勃生物(Probio Cayman)发生股权转让,高瓴资本及其联合体持有的蓬勃生物3亿股A类优先股将以约17亿港元转让给金斯瑞及其全资控股子公司,股权转让基于蓬勃生物整体估值16.84亿美元。本次交易的3亿股份可...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10